Abstract
RH1 and MeDZQ represent novel aziridinylbenzoquinones that can be activated by DT-diaphorase to form unique DNA lesions. RH1 is due to enter a phase 1 clinical trial in the United Kingdom in the summer of 2003, where pharmacodynamic monitoring of DT-diaphorase will be performed.
Original language | English |
---|---|
Pages (from-to) | 3979-83 |
Number of pages | 5 |
Journal | Anticancer research |
Volume | 23 |
Issue number | 5A |
Publication status | Published - 2003 |
Keywords / Materials (for Non-textual outputs)
- Animals
- Antineoplastic Agents
- Aziridines
- Benzoquinones
- Carcinoma, Non-Small-Cell Lung
- Colonic Neoplasms
- Dose-Response Relationship, Drug
- Female
- Humans
- Lung Neoplasms
- Mice
- Mice, Nude
- NAD(P)H Dehydrogenase (Quinone)
- Transplantation, Heterologous
- Xenograft Model Antitumor Assays